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Summary
Recent studies of oncogene dependence in conditional transgenic mice have suggested the exciting possibility that
transient or prolonged MYC inactivation may be sufficient for sustained reversal of the tumorigenic process. In contrast,
we report here that following oncogene downregulation, the majority of c-MYC-induced mammary adenocarcinomas grow
in the absence of MYC overexpression. In addition, residual neoplastic cells persist from virtually all tumors that do regress
to a nonpalpable state and these residual cells rapidly recover their malignant properties following MYC reactivation or
spontaneously recur in a MYC-independent manner. Thus, MYC-induced mammary tumor cells subjected to either brief
or prolonged MYC inactivation remain exquisitely sensitive to its oncogenic effects and characteristically progress to a
state in which growth is MYC-independent.
Introduction To determine experimentally whether invasive tumors re-
main dependent upon individual oncogenic pathways for their
Human cancers arise through a multistep process involving the maintenance, several transgenic mouse models for cancer have
sequential activation of oncogenes and inactivation of tumor recently been developed based upon the conditional overex-
suppressor genes. Consequently, novel therapeutic approaches pression of oncogenes such as c-MYC, Kras2, Hras, and BCR-
are increasingly being devised to reverse the effects of individual ABL within a variety of cell types. Each of these studies has
genetic alterations by specifically targeting oncogenic pathways demonstrated that inactivation of a single oncogene within a
that become activated within particular tumor types. With the primary tumor canbe sufficient to inducedramatic tumor regres-
advent ofmolecularly targeted therapies for cancer, the question sion (Chin et al., 1999; D’Cruz et al., 2001; Felsher and Bishop,
of whether invasive tumors remain dependent upon a single 1999a; Fisher et al., 2001; Gunther et al., 2003; Huettner et al.,
oncogenic pathway for maintenance and growth has become 2000; Jain et al., 2002; Moody et al., 2002; Pelengaris et al.,
a critical issue in cancer therapeutics. In principle, reversing a
1999, 2002). Moreover, oncogene dependence also occurs insingle genetic lesion that activates a dominant oncogenic path-
tumors in which a second, independent oncogenic pathwayway within a tumor could lead to sustained tumor regression.
has been activated or a tumor suppressor pathway has beenAlternately, oncogenic pathways critical for tumor induction
inactivated (Fisher et al., 2001; Gunther et al., 2003; Pelengariscould become dispensable for maintenance of the neoplastic
et al., 2002). Surprisingly, even advanced stages of malignancy,state once tumors have formed. Similarly, tumors that initially
such as metastases, can remain dependent upon an initiatingexhibit dependence upon an oncogenic pathway may subse-
oncogenic event for maintenance and growth (Moody et al.,quently progress to a state in which growth becomes resistant
2002, Gunther et al., 2003). In aggregate, conditional transgenicto pathway inhibition, as is commonly observed during the treat-
ment of human cancers. mouse models analyzed to date support the concept that tar-
S I G N I F I C A N C E
Molecular therapeutics that target specific oncogenic pathways hold considerable promise. The success of such approaches,
however, depends on the extent to which malignant cells remain dependent upon individual oncogenic mutations. Since c-MYC
overexpression occurs commonly in human breast cancers, the question of whether MYC inactivation represents an effective
treatment for this disease has considerable clinical importance. In contrast to other cell types, neither brief nor prolonged MYC
inactivation in mammary adenocarcinomas results in sustained tumor regression or protection against MYC’s oncogenic effects.
Our studies emphasize that clinically important properties of tumors arise from small, yet biologically critical, subsets of cells and
suggest that secondary pathways of tumor escape represent a significant obstacle to the efficacy of targeted therapeutics for
cancer.
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geted inactivation of a single, dominant oncogenic pathway— tive—or perhaps even preferable—treatment for human can-
cers.the so-called “Achilles heel” of cancers—may lead to the sus-
tained regression of tumors harboring multiple genetic and In light of this proposal, we wished to consider whether the
above findings could be extrapolated to a common epithelialepigenetic alterations (Weinstein, 2002). The relevance of this
concept to at least some human cancers has been illustrated cancer in which c-MYC has been implicated. c-MYC amplifica-
tion occurs in 5%–15% percent of human breast cancers, andby the dramatic clinical responses observed in patients with
chronic myelogenous leukemia (CML) treated with the tyrosine this oncogene is overexpressed in themajority of breast cancers
in women (Liao and Dickson, 2000). Moreover, while osteogenickinase inhibitor, imatinib (Druker et al., 2001; Kantarjian et al.,
2002). sarcoma is rare, breast cancer is the most common malignancy
diagnosed amongwomen in the United States and is the leadingThe finding that even advanced stages of tumorigenesis
can remain sensitive to molecularly targeted interventions is an cause of death from disease among women aged 25 to 54. As
such, whether brief or prolonged inactivation of c-MYC mightencouraging proof-of-principle that such targeted agents can
be effective. Nevertheless, clinical experience with common represent an effective treatment for breast cancer is a question
of considerable clinical importance.epithelial malignancies has been far less encouraging. Indeed,
the natural history of most human cancers entails the progres- To investigate this issue, we have developed a transgenic
mouse model in which c-MYC can be conditionally overex-sive selection and outgrowth of malignant subsets of tumor
cells that possess increasingly aggressive properties. These pressed in themammary glands ofmice treatedwith tetracycline
derivatives (D’Cruz et al., 2001). We report here that the majorityinclude the development of therapeutic resistance, occurrence
of distant metastasis, establishment and prolonged survival of of c-MYC-induced primary mammary adenocarcinomas that
arise in mice are already able to grow in the absence of MYCresidual neoplastic cells within the host and, ultimately, tumor
recurrence. Together, these aspects of tumor progression are overexpression, that the majority of tumors that do fully regress
following MYC downregulation recur spontaneously, that mostresponsible for the vast majority of cancer deaths. Thus, in
contrast to patients with CML treated with imatinib, patients if not all animals bearing fully regressed tumors harbor residual
neoplastic cells, and that reactivation of MYC in these residualwith metastatic cancers of the breast, lung, colon, prostate, and
pancreas—which together account for nearly two-thirds of all cells results in the rapid and full recovery of their malignant proper-
ties. Furthermore, successive cycles ofMYC transgene expressioncancers inWestern countries—are rarely if ever cured by combi-
nation therapy, much less therapy with a single agent. Rather, resulted in the progression of nearly all MYC-induced mammary
tumors to a doxycycline-independent state. As such, rather thanclinical observations repeatedly indicate that subsets of cells
within genetically heterogeneous tumors become resistant to exerting a protective effect on neoplastic mammary epithelial
cells, c-MYC-induced tumors cells subjected to either brief ortherapy by escaping the selective pressures that therapeutic
interventions represent. Viewed from this perspective, lessons prolonged MYC inactivation remain exquisitely sensitive to its
oncogenic effects and characteristically progress to a state infrom mouse models—while encouraging—would seem at odds
with lessons from the clinic. which MYC overexpression is dispensable for growth. These
findings emphasize the context-dependent nature of oncogenePerhaps nowhere is this discrepancy more apparent than
in studies of conditional transgenic models for c-MYC-induced dependence as well as the ability of mouse models to faithfully
recapitulate the natural history of human cancers.tumorigenesis. The c-MYC transcription factor has been inten-
sively studied due to its demonstrated role in multiple human
cancers as well as in cellular processes central to cancer, such Results
as cell growth, proliferation, differentiation, and apoptosis (Pel-
engaris and Khan, 2003a, 2003b). Inducible transgenic models The majority of MYC-induced primary mammary
tumors are MYC-independentfor c-MYC have been described for hematopoietic, epidermal,
pancreatic islet, and osteogenic sarcoma cells, among others Wehavepreviously reported the generation and initial character-
ization of a bitransgenic system for the conditional expression(Felsher and Bishop, 1999a; Jain et al., 2002; Pelengaris et al.,
1999, 2002). Based upon these models, it has been proposed of c-MYC in themammary gland utilizing the tetracycline regula-
tory system (D’Cruz et al., 2001). In this model, the reversethat c-MYC-induced neoplasms remain dependent upon
c-MYC transgene expression for maintenance of the malignant tetracycline-dependent transcriptional activator, rtTA, is ex-
pressed from the mouse mammary tumor virus (MMTV) pro-state, and that sustained MYC downregulation leads to sus-
tained tumor regression and elimination of neoplastic cells from moter and, in the presence of doxycycline, induces expression
of a c-MYC transgene fused to a tetracycline-dependent pro-the host (Weinstein, 2002).
More provocative still has been the surprising recent report moter. Chronically induced MMTV-rtTA/TetO-MYC (MTB/TOM)
bitransgenic animals develop solitary mammary adenocarcino-that even brief periods of c-MYC inactivation in osteogenic
sarcoma cells result in sustained tumor regression (Jain et al., mas with a mean latency of 22 weeks in a manner that is abso-
lutely dependent upon transgene induction by doxycycline.2002). Surprisingly, reactivation of MYC in residual tumor cells
in this system failed to restore their malignant properties and Following the removal of doxycycline from thedrinkingwater
of tumor-bearing bitransgenic animals, 31 of 62 deinducedinstead induced apoptotic cell death. These findings have been
taken to support the exciting possibility that brief inactivation mammary adenocarcinomas failed to regress to a nonpalpable
state (Figure 1A). The extent of regression among incompletelyof MYC may not only be therapeutic, but may in addition exert
a protective effect that renders previously neoplastic cells insen- regressing tumors was variable and formed a continuous range
from90% regression (e.g., tumors 32–42) to10% regressionsitive to the tumorigenic properties of this oncogene. Based
upon these observations, it has been proposed that transient (e.g., tumors 61 and 62). Northern hybridization analysis of in-
completely regressing tumors before and after doxycyclinewith-inactivation of an oncogenic pathway may represent an effec-
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drawal confirmed the sustained downregulation of c-MYC trans-
gene expression and MYC target genes, and the absence of
overexpression of endogenous c-myc (D’Cruz et al., 2001 and
data not shown). Thus, in contrast to findings in other cell types
in which c-MYC inactivation leads almost invariably to the com-
plete reversal of malignant lesions, half of c-MYC-induced pri-
mary mammary adenocarcinomas fail to regress fully following
c-MYC transgene downregulation.
Given differences in the observed oncogene dependence
of c-MYC-induced mammary adenocarcinomas compared to
c-MYC-induced neoplasms in other tissues, we considered the
possibility that failure to regress to a nonpalpable lesion might
not represent a clinically significant endpoint; that is, despite
their failure to regress fully, some or all incompletely regressing
tumors may nevertheless have lost their capacity for malignant
growth following the abrogation of c-MYC transgene expres-
sion. To investigate this possibility, tumor-bearing mice were
followed for extended periods of time following doxycycline
withdrawal. This analysis revealed that, in addition to their failure
to regress fully following MYC inactivation, incompletely re-
gressing tumors rapidly reinitiated growth in the absence of
MYC transgene expression (Figure 1B). Specifically, within 40
days following doxycycline withdrawal, nearly all tumors classi-
fied as incompletely regressing had resumed growth, increasing
in size an average of 2.3 cm3 over this period compared to their
minimum size following transgene deinduction (Figure 1C). In
contrast, none of the tumors classified as fully regressing exhib-
ited any substantial regrowth over this period (p value for incom-
pletely regressing versus fully regressing tumors  6.9  107,
Figure 1C). These findings demonstrate that the majority of
primary mammary tumors that arise as a consequence of MYC
activation have already acquired the ability to grow in the ab-
sence of MYC overexpression. This, in turn, suggests that pro-
longed c-MYC inactivation has markedly different consequences
in mammary tumors compared to MYC-induced neoplasms of
other tissues.
Fully regressed MYC-induced mammary tumors
recur spontaneously
Although half of MYC-induced primary mammary tumors that
have reached 1 cm3 in size have already acquired the ability to
grow in the absence of c-MYC overexpression, it remained
possible that those tumors that did regress to a nonpalpableFigure 1. MYC-induced mammary adenocarcinomas resume growth fol-
lowing MYC downregulation state following transgene deinduction might exhibit sustained
regression similar to that described for MYC-induced neo-A: Sixty-two c-MYC-induced tumors were monitored for tumor regression
following doxycycline withdrawal. Extent of tumor regression was calcu- plasms of other tissues (Felsher and Bishop, 1999a; Jain et al.,
lated as a percentage by dividing the minimum tumor volume reached 2002; Pelengaris et al., 2002). To determine whether tumors
following doxycycline withdrawal by tumor size at deinduction. Note that
that were initially dependent on c-MYC transgene expression50% of the tumors fail to regress fully followingc-MYC transgene deinduction.
would remain so, bitransgenic animals harboring fully regressedB: Extent of tumor regrowth off doxycycline was measured in the 62 c-MYC-
induced mammary adenocarcinomas in A. Tumor growth is expressed as mammary adenocarcinomas were monitored for spontaneous
the difference between tumor volume at 40 days postdeinduction and the tumor recurrences off doxycycline. Within one year following
minimum size reached following deinduction. Note that nearly all incom- doxycycline withdrawal, greater than 50% of fully regressedpletely regressing tumors resumed growth by 40 days, whereas fully re-
tumors had recurred at the site of the original primary tumorgressing tumors did not.
C: The mean growth of deinduced tumors at 40 days postdeinduction was (Figure 2A). The median time to recurrence was 80 days follow-
calculated for incompletely regressing and fully regressing c-MYC-induced ing doxycycline withdrawal (range 45–330 days; n  16). All
mammary adenocarcinoma subsets (student’s t test, p  6.88  107). recurrent tumors exhibited a high rate of growth regardless of
their time to recurrence (Figure 2B).
Four lines of evidence suggest that these tumors repre-
sented bona fide recurrences rather than de novo neoplasms
arising off doxycycline. First, recurrent tumors always arose at
the site of the original primary tumor; second, no tumors arose
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in bitransgenic animals in the absence of doxycycline treatment;
third, tumors that were grafted into syngeneic hosts, allowed
to grow on doxycycline, and then deinduced were also found
to recur spontaneously (data not shown); and fourth, for those
primary tumors biopsied prior to doxcycline withdrawal in which
Nras mutations were identified, the identical Nras mutation was
also found in the recurrent tumor (data not shown). Together,
these findings strongly suggest that tumors reappearing at the
site of a fully regressed tumor inmicemaintained off doxycycline
represent genuine recurrences. Furthermore, the observation
that most fully regressedMYC tumors recur spontaneously indi-
cates that the regression of primary tumors following oncogene
downregulation—though dramatic—is incomplete, leaving via-
ble residual neoplastic cells at the site of the original tumor.
MYC-induced tumors recur by MYC-dependent
and MYC-independent mechanisms
To determine whether tumor recurrences occur as a result of
MYC overexpression or by a pathway independent of MYC
overexpression, we performed Northern hybridization on RNA
isolated from recurrent tumors using a radiolabeled fragment
of c-MYC exon 2 that detects expression of both the MYC
transgene and endogenous c-myc. Overexpression ofMYCwas
absent in 13 of 16 recurrent tumors (Figure 2C, upper panel,
and data not shown). To determine whether elevated c-MYC
transcript levels resulted from upregulation of endogenous
c-myc or from reactivation of theMYC transgene in the absence
of doxycycline treatment, Northern blots were probed with a
cDNA fragment specific for endogenous c-myc (Figure 2C, mid-
dle panel). Consistent with myc’s ability to repress its own tran-
scription, expression of endogenous c-myc was suppressed
in all three recurrent tumors exhibiting high levels of c-MYC
expression. This finding confirms that these tumors had reacti-
vated theMYC transgene in a doxycycline-independent manner
rather than upregulating endogenous c-myc. Consistent with
this, the remaining 13 recurrent tumors exhibited endogenous
c-myc levels comparable to those found in carcinogen-induced
mammary adenocarcinomas (Figure 2C, middle panel). To-
gether, these results suggest that the majority of MYC-induced
tumors recur by aMYC-independent mechanism and that resid-
ual neoplastic cells persist following the regression of MYC-
induced tumors and can eventually circumvent their requirementFigure 2. Fully regressed c-MYC-induced mammary tumors spontaneously
for MYC overexpression for neoplastic growth.recur
It has previously been reported that osteogenic sarcomaA: Tumor-free survival curve following doxycycline withdrawal for MTB/TOM
cells in which the c–MYC transgene has been inactivated aremice bearing fully regressed mammary adenocarcinomas (n  51). Age-
matched uninduced MTB/TOM mice are shown as controls (n  24). protected against the malignant properties of this oncogene
B: Growth chart showing the timing of recurrent c-MYC-induced tumor following MYC transgene reactivation (Jain et al., 2002). How-
growth. Tumor volumes were measured following doxycycline withdrawal.
ever, we noted that 3 of 16 recurrent mammary tumors ex-C: Northern analysis performed on total RNA from fully regressed c-MYC-
pressed theMYC transgene at levels comparable to those foundinduced mammary adenocarcinomas that recurred in the absence of dox-
in tumor-bearing animals maintained on doxycycline (Figure 2Cycycline. The blot was probed with a radiolabeled c-MYC fragment that
recognizes both the c-MYC transgene and endogenous c-myc (top panel). upper panel). Thus, in contrast to osteogenic sarcoma cells, the
Three of fourteen recurrent tumors demonstrated reactivation of the c-MYC spontaneous reactivation of c-MYC transgene expression in a
transgene in the absence of doxycycline. A duplicate Northern blot was
subset of recurrent c-MYC-induced adenocarcinomas suggestsprobed with a radiolabeled fragment from exon 1 of c-myc that recognizes
not only that residual mammary tumor cells are not protectedendogenousc-myc, but not thec-MYC transgene (middle panel). Note that
from c-MYC’s tumorigenic effects, but that reactivation of MYCexpression of c-myc in the eleven recurrent mammary adenocarcinomas
without reactivation of the MYC transgene is comparable to that seen in within residual tumor cells is actually selected for as a means
nontransgenic tumors induced by the carcinogen, DMBA, whereas endog- of mammary tumor recurrence.
enous c-myc expression is suppressed in the three recurrent mammary ade-
nocarcinomas that had reactivated the MYC transgene in the absence of
Residual neoplastic tumor cells remaindoxycycline. Paired samples from a c-MYC-induced tumor harvested on
susceptible to c-MYCdoxycycline and 7 days after doxycycline withdrawal during the regression
phase are shown as controls. Ethidium bromide stained 28S rRNA bands are As noted above, even brief inactivation of c-MYC has been
shown as loading controls (bottom panel). reported to protect osteogenic sarcoma cells fromMYC’s onco-
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genic properties due to MYC’s ability to induce apoptosis in
residual tumor cells following its reactivation (Jain et al., 2002).
Since c-MYC expression is required for the proliferation of nor-
mal cells, these findings have important clinical implications, as
they argue that long-term inactivation of c-MYC may not be
required for effective cancer therapy and that transient MYC
inactivation may actually confer greater antitumor effects than
sustainedMYC inactivation. In contrast, the spontaneous reacti-
vation of c-MYC transgene expression that we observed in re-
current mammary adenocarcinomas suggests that residual tu-
mor cells remain susceptible to this oncogene.
To further address whether residual mammary tumor cells
are protected from MYC’s oncogenic properties, doxycycline
was readministered to eight bitransgenic animals bearing fully
regressed mammary adenocarcinomas. In all cases, tumors re-
appeared at the site of the original tumor with an average latency
of six days, far shorter than the 22-week latency required for
primary tumor formation (Figures 3A and 3B). Furthermore, in
bitransgenic animals in which mammary adenocarcinomas had
remained nonpalpable for at least six months, reactivation of
c-MYC resulted in the rapid recurrence of tumors in five out
of six animals (data not shown). These observations strongly
suggest that residual neoplastic cells remain viable for long
periods of time at the site of the regressed primary tumor and
are only one step away from reacquiring their full malignant
potential. Our findings indicate that virtually all animals bearing
fully regressed mammary tumors harbor residual neoplastic
cells that persist at the site of the original tumor, and that these
latent mammary tumor cells remain highly susceptible to the
malignant properties of MYC following either brief or sustained
periods of c-MYC inactivation. Thus, unlike osteogenic sarcoma
cells, transient inactivation of c-MYC is not sufficient to protect
mammary epithelial cells from the oncogenic consequences of
its reactivation.
The protection against MYC’s oncogenic effects observed
in osteogenic sarcoma cells has been attributed toMYC’s ability
to induce apoptosis in cells in which its expression had been
reactivated (Jain et al., 2002). Thus, one possible explanation
for the lack of protection seen in residual mammary tumor cells
is that these cells are no longer susceptible to c-MYC-induced
apoptosis. However, TUNEL analysis of recurrent mammary
adenocarcinomas arising in reinduced bitransgenic animals re- Figure 3. Residual neoplastic cells remain susceptible to MYC
vealed levels of apoptosis comparable to those observed in A: Tumor-free survival curve for MTB/TOM animals bearing fully regressed
primary c-MYC-induced mammary adenocarcinomas (Figure tumors that were readministered doxycycline (n  8). MTB/TOM mice, ad-
ministered doxycycline for the first time, are shown as controls (n  15).3C). This suggests that the lack of protection against MYC’s
B: Increase in tumor volume for representative tumors followingc-MYC trans-malignant properties observed among residual mammary tumor
gene reactivation (n  6).
cells is not due to their inability to undergo apoptosis. C:Apoptosis rates remain high inc-MYC-induced mammary adenocarcino-
mas following MYC transgene reactivation. Note comparable numbers of
TUNEL-positive cells in representative sections from a c-MYC-induced mam-MYC-induced tumors progress following repeated
mary tumor sequentially biopsied during the initial induction of c-MYC trans-exposure to c-MYC
gene (left) and following reactivation of the MYC transgene subsequentTumors in inducible transgenic systems have been reported to
to a period of MYC transgene inactivation (right).
retain their dependence on an initiating oncogene even after
serial passage in syngeneic hosts, suggesting that oncogene
dependence is a stable characteristic of tumors (Felsher and
Bishop, 1999a). Since mammary epithelial cells are not pro- overexpression (i.e., had regressed to a nonpalpable state fol-
tected fromc-MYC’smalignant properties followingMYC inacti- lowing doxycycline withdrawal) would progress to aMYC trans-
vation, we considered whether mammary tumor cells subjected gene-independent state following additional periods of expo-
to repeated rounds of exposure to MYC would progress to sure toMYC (Figure 4A). We anticipated that this protocol would
a state in which tumor growth became independent of MYC approximate the situation in which patients are exposed to mul-
transgene overexpression. To address this question, we evalu- tiple courses of antineoplastic therapy as typically occurs during
the course of cancer treatment.ated whether tumors that were initially dependent upon c-MYC
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51% of mice in which tumors had regressed to a nonpalpable
state following the first cycle of transgene induction and dein-
duction. Consistent with our previous finding that residual tumor
cells remain sensitive to the oncogenic effects of MYC, all tu-
mors rapidly regrew at their original sites following MYC reacti-
vation (Figure 4A). When reinduced recurrent tumors reached
1 cm3 in size, transgene expression was again abrogated by
doxycycline withdrawal. Following this second round of c-MYC
transgene induction and deinduction, 35% of tumors that had
fully regressed following the first round of exposure to MYC
failed to regress fully in response to the second period of MYC
downregulation (Figure 4B).
To determine whether the remaining MYC-dependent tu-
mors would progress to a doxycyline-independent state, the
process of c-MYC transgene induction and deinduction was
repeated for a third time in mice whose tumors had fully re-
gressed for two consecutive cycles. Fifty percent of tumors that
had fully regressed during the first two rounds of deinduction
failed to regress fully following the third round of doxycycline
withdrawal (Figure 4B). Thus, after three cycles of c-MYC trans-
gene induction and deinduction, 83% of c-MYC-induced mam-
mary adenocarcinomas had acquired the ability to grow in the
absence of doxycycline. Northern hybridization analysis for the
c-MYC transgene, endogenous c-myc, and the MYC target
gene, Shmt1, demonstrated that only a single tumor in each
round of deinduction had reactivated the Myc pathway in the
absence of doxycycline and that all remaining tumors exhibited
reduced activity of the Myc pathway (data not shown). The
doxycycline-independent reactivation of MYC transgene ex-
pression in occasional tumors further highlights the fact that
Figure 4. Mammary tumors progress to a MYC-independent state following residual tumor cells remain exquisitely sensitive to themalignant
repeated cycles of MYC expression properties of c-MYCdespite single ormultiple periods of c-MYC
A: Representative tumor growth curves for c-MYC-induced mammary ade- inactivation. Moreover, our findings also indicate that the vast
nocarcinomas that acquire the ability to grow in a MYC-independent man-
majority of c-MYC-induced mammary adenocarcinomas do notner following one (black), two (orange), or three (blue) cycles of MYC
remain dependent upon c-MYC transgene expression followingtransgene induction and deinduction.
B: Chart demonstrating the per-cycle and cumulative percentage of repeated exposures to c-MYC, and instead progress to a trans-
c-MYC-induced mammary adenocarcinomas that become MYC-indepen- gene-independent state.
dent during each round of MYC transgene induction and deinduction.
Blue bars represent the percentage of tumors that grew independently of
Kras2 activation contributes to MYC-independentdoxycycline treatment in each deinduction cycle; maroon bars represent
growth in a subset of tumorsthe cumulative percentage of tumors that grew independently of doxycy-
cline treatment by that cycle of induction/deinduction. We have previously demonstrated that the presence of an acti-
vating point mutation in Kras2 tightly correlates with the inability
of primary MYC-induced mammary adenocarcinomas to re-
gress fully following MYC transgene deinduction (D’Cruz et al.,
Bitransgenic animals were induced with doxycycline until 2001). Thus, we considered the possibility that the progression
mammary tumors developed and were deinduced when tumors of tumors that were initially MYC-dependent to aMYC-indepen-
reached 1 cm3 in size. In those mice in which tumors fully re- dent state could be due to the outgrowth of cells harboring
gressed, MYC expression was reinduced. When doxycycline- activating Kras2mutations. As such, we evaluated the contribu-
induced tumor recurrences reached 1 cm3 in size, transgene tion ofKras2mutations to the loss of MYC dependence in MYC-
expression was again abrogated by doxycycline withdrawal. induced tumors in two different experimental contexts. First,
This process of sequential MYC activation and inactivation was we determined Kras2 mutation status in primary tumors that
repeated for three successive cycles. Incompletely regressing were MYC-independent at the first time of doxycycline with-
tumors from each roundwere assayed byNorthern hybridization drawal, as well as in MYC-independent recurrences that arose
for expression of the c-MYC transgene, endogenous c-myc, and from primary tumors that had regressed to a nonpalpable state
the MYC target gene, Shmt1, to determine whether doxycycline in micemaintained off doxycycline (Figure 2 and Table 1). Exons
independence correlated with downregulation of the c-MYC 1 and 2 of Kras2 were amplified and sequenced to look for
pathway. activating point mutations at codons 12, 13, and 61. Consistent
As in prior studies, following a single round of transgene with our previous findings, Kras2 mutations were identified in
induction and deinduction, 31 of 65 (49%) c-MYC-induced tu- 67% (18 of 27) of incompletely regressing primary tumors (Table
mors resumed growth in the absence of doxycycline (Figure 1). In contrast, only 25% (3 of 12) of spontaneous recurrences
were found to have activating point mutations in Kras2 (2 4B). Transgene expression was then reinduced in the remaining
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Table 1. Kras2 mutation status of c-MYC independent tumors
Experiment 1: Spontaneous Kras2 mutation status
tumor recurrence
Primary, incompletely 67% (18/27)
regressing tumors
Spontaneous tumor 25% (3/12)
recurrences
Experiment 2: Repeated MYC Kras2 mutation status
induction/deinduction
Incompletely regressing tumors 50% (8/16)
(1st round of deinduction)
Figure 5. Transgene-independent MYC-induced mammary tumors remainIncompletely regressing tumors 29% (2/7)
diploid(2nd or 3rd round of deinduction)
The ploidy of c-MYC-induced mammary adenocarcinomas was deter-
mined by flow cytometric analysis of propidium iodide-stained nuclei. No
aneuploidy was detected from nuclei of 38 tumors, 16 of which were depen-
dent on c-MYC transgene expression for maintenance of the oncogenic
state and 22 of which exhibited c-MYC transgene-independent growth. A4.25, p  0.04). Thus, while acquisition of Kras2 mutations
representative DNA histogram for a c-MYC transgene independent tumorappears to account for the progression to MYC independence
is shown (left). A tetraploid mammary tumor with known p53 loss-of-hetero-
in two-thirds of primary MYC-induced tumors, a significantly zygosity was evaluated as a positive control (right).
smaller fraction of recurrent mammary tumors achieves MYC
independence by this mechanism. This suggests that mecha-
nisms other than Kras2 mutation contribute to spontaneous
tumor recurrence in the majority of cases, and highlights the pensity of c-MYC-induced mammary adenocarcinomas to
progress to transgene independence was a consequence ofpossibility that mechanisms of escape from MYC-dependence
may differ between primary and recurrent tumors. MYC’s ability to induce genomic instability. Evaluation of the
DNA content of nuclei from c-MYC-induced mammary adeno-To investigate this issue further, we determined the Kras2
mutation status of mammary tumors that had progressed to carcinomas by propidium iodide staining revealed that the vast
majority of cells within c-MYC-induced mammary adenocarci-MYC independence following multiple rounds of exposure to
MYC (Figure 4 and Table 1). Activating point mutations in Kras2 nomas have a diploid DNA content (Figure 5 and data not
shown). Of 38 MYC-induced mammary adenocarcinomas (22were assayed in MYC-induced primary tumors that were MYC-
independent following the first cycle of MYC induction and dein- of which exhibited c-MYC-independent growth), no tumor dis-
played evidence of gross genomic instability. Therefore, weduction, and in tumors that became MYC-independent during
the second or third cycles of MYC induction and deinduction. conclude that c-MYC does not promote the progression of
mammary tumors to transgene independence by destabilizingWe found that while 50% of MYC-independent primary mam-
mary tumors harbored Kras2 mutations (8 of 16), Kras2 muta- the genome.
tions were identified in only 29% (2 of 7) of tumors that became
MYC-independent in cycles 2 or 3. Our results suggest thatwhile Discussion
Kras2 mutation represents one mechanism by which tumors
becomeMYC-independent following sequential rounds of MYC The natural history of human cancers is characterized by the
progressive selection and outgrowth of cells that possess in-exposure, the majority of tumors that acquire MYC-indepen-
dence in this context do so by mechanisms other than Kras2 creasingly aggressive properties, such as loss of hormone de-
pendence, resistance to chemotherapeutic agents, and the abil-mutation. In aggregate, our data argue that multiple mecha-
nisms exist by which MYC-induced mammary tumors escape ity to invade tissues and metastasize. Moreover, residual cells
from cancers that have responded to therapy frequently havetheir dependence on MYC, and that Kras2 mutation becomes
a less commonly used pathway of tumor escape in recur- the ability to survive and remain dormant within tissues for long
periods of time and then subsequently resume growth. It isrences—both spontaneous and induced—compared to primary
tumors. precisely these clinical manifestations of tumor progression that
are responsible for the vast majority of cancer deaths.
Unlike the tendency of human cancers to progress to moreMYC-independent mammary tumors do not exhibit
gross genomic instability aggressive states that are resistant to therapy, and despite the
multistep nature of carcinogenesis, inactivation of MYC in ex-It has previously been suggested that MYC-induced tumors that
arise as a consequence of this oncogene’s ability to promote perimental tumor systems has previously been shown to be
sufficient to reverse the malignant properties of MYC-initiatedcellular proliferation and inhibit differentiation may remain de-
pendent upon c-MYC, whereas tumors that arise as a conse- lesions of epidermal, hematopoeitic, pancreatic islet, and os-
teogenic sarcoma cells (Felsher and Bishop, 1999a; Jain et al.,quence of c-MYC’s ability to promote genomic instability may
become MYC-independent (Jain et al., 2002). In support of 2002; Pelengaris et al., 2002). This has been taken as evidence
that cancers can become “addicted” to the oncogenes thatthis model, transient exposure of an immortalized cell line to
increased c-MYC activity has been shown to induce chromo- initiated them, thereby predisposing such tumors to a remark-
able degree of dependence upon single oncogenic pathways.somal abnormalities and aneuploidy and to promote tumorigen-
esis in the absence of continued c-MYC expression (Felsher Consequently, it has been proposed that transient inactivation
of dominant oncogenic pathways within tumors may representand Bishop, 1999b). Therefore, we considered whether the pro-
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an effective—if not preferable—treatment for human cancers. dependent nature of tumor regression followingMYC transgene
inactivation.This inference has particular significance for the clinic, since
oncogene downregulation in experimental tumor systems can A particularly critical feature of human epithelial cancers is
the ability of residual neoplastic cells to survive and persist inin some ways be seen to simulate idealized pharmacological
inhibitors capable of efficiently blocking oncogenic pathways the host in a presumed quiescent state following the apparently
successful treatment of the primary tumor. Ultimately, theseof interest. From this perspective, oncogene downregulation in
conditional transgenic systems represents a genetic paradigm residual neoplastic cells reemerge from their dormant state and
resume growth, leading to cancer recurrence. Indeed, a signifi-for the effects of molecularly targeted therapies.
In contrast to findings in hematopoeitic, pancreatic islet, cant fraction of breast cancers in women recur 10 years or more
following treatment of the primary tumor. Analogous to thisand osteogenic sarcoma cells in which virtually all MYC-induced
tumors demonstrate initial MYC dependence, we report here phenomenon, we report here that a subset of MYC-induced
tumors that have regressed to a nonpalpable state followingthatmostMYC-inducedprimarymammary tumors fail to regress
fully despiteMYC inactivation. Furthermore, while tumor relapse MYC downregulation recur spontaneously in the absence of
transgene expression over periods of up to one year. Our obser-has been noted in only 10%–20% of c-MYC-induced lympho-
mas, recurrence of MYC-induced mammary tumors occurs as vations further indicate that most, if not all, animals bearing fully
regressed tumors harbor residual neoplastic disease long afterthe rule rather than the exception (Felsher and Bishop, 1999a;
Jain et al., 2002; Karlsson et al., 2003; Pelengaris et al., 2002). the apparently complete regression of their tumors. Residual
neoplastic cells and tumor recurrences have also been observedNotably, mammary tumor recurrences arise as a consequence
of the presence of residual neoplastic cells that persist in the in animals bearing fully regressed Neu, Wnt1, and Ras-induced
mammary tumors (Gunther et al., 2003; Moody et al., 2002;mammary glands of nearly all animals harboring fully regressed
tumors. Moreover, reactivation of MYC in these residual cells and data not shown). Thus, the behavior of tumors in these
conditional mouse models parallels the natural history of humanresults in their rapid resumption of neoplastic growth, indicating
that these cells remain exquisitely sensitive toMYC’s oncogenic breast cancer and highlights the importance of understanding
the mechanisms responsible for tumor recurrence.effects. Thus, unlike the remarkable oncogene dependence ob-
served for MYC-initiated hematopoietic and osteogenic sar- In this regard, we have found that activating point mutations
in Kras2 contribute to the acquisition of MYC independence incoma cells, the majority of MYC-induced mammary tumors
progress to a state in which MYC overexpression is dispensable spontaneous tumor recurrences arising from residual neoplastic
cells, and in tumor cells that escape their dependence uponfor growth. Our findings suggest that transient pharmacological
inactivation ofMYCmay not be an effective treatment for human MYC following multiple rounds of exposure to this oncogene.
However, while Kras2 mutation contributes to the acquisitionbreast cancers in which this oncogene plays a dominant role,
and emphasize that oncogene dependence is likely to be highly of MYC-independence in both primary and recurrent tumors, it
appears to be a considerably more common mechanism in thecontext-dependent.
Why then do MYC-induced experimental tumors of different former than the latter. That is, in most cases, mechanisms other
than Kras2 mutation account for the ability of tumor recurrencetissues differ in the extent to which they remain dependent upon
this oncogene? One possibility is that differences in oncogene to escape their dependence on MYC, thereby highlighting the
possibility that mechanisms of escape from oncogene depen-dependence are due to differences in the response of different
tumor types to MYC downregulation. For example, sustained dence may differ between primary tumors and recurrences.
Future analyses aimed at elucidating the oncogenic pathwaystumor regression in osteogenic sarcoma cells following MYC
transgene inactivation is accompanied by differentiation of that become dominant in recurrent tumors will help identify
additional pharmacologic targets for the treatment of this deadlythese cells to mature osteocytes (Jain et al., 2002). In contrast,
epithelial differentiation is not universally seen following MYC aspect of tumor progression.
To the extent that oncogene downregulation in conditionaldownregulation in mammary tumors. As such, the difference in
response to c-MYC inactivation observed in osteogenic sar- transgenic systems simulates the effects ofmolecularly targeted
therapies, our findings have several implications for the usecoma and mammary adenocarcinoma cells may be explained
by a failure ofmammary tumor cells to undergo terminal differen- of such therapies. First, our observations that transient MYC
inactivation does not result in sustained tumor regression andtiation following MYC downregulation.
The long latency of mammary tumor formation following that residual neoplastic cells remain highly susceptible to the
oncogenic effects of MYC suggest that common human epithe-MYC overexpression suggests that additional genetic changes
are required for neoplastic transformation. These secondary lial cancers will require chronic rather than transient treatment
with molecularly targeted agents. Second, our observation thatgenetic events could, in theory, contribute to tumor progression
as well as tumor initiation. Specifically, such mutations could prolonged MYC inactivation also fails to result in sustained tu-
mor regression and that the great majority of MYC-inducedreplace MYC as the dominant oncogenic pathway within the
tumor and in this way contribute to tumor progression and the mammary tumors progress to a state in which MYC overexpres-
sion is dispensable for growth suggests that treating humantransition to oncogene independence. In this regard, we have
previously reported that the incomplete regression of c-MYC- cancers with single molecularly targeted agents will likely fail.
As such, our findings indicate that effective antineoplastic ther-induced mammary adenocarcinomas correlates with the pres-
ence of spontaneous activating point mutations in Kras2. The apy will require combining agents that target dominant onco-
genic pathways with agents that target secondary pathways ofoccurrence of suchmutations has not been reported for lympho-
mas, leukemias, or islet cell tumors initiated by MYC. Thus, tumor escape, or that eliminate residual neoplastic disease.
Third, the survival of residual neoplastic cells following tumordifferences in the mutations that accompany MYC-induced tu-
morigenesis in different tissues could explain the context- regression emphasizes that oncogene inactivation is not capa-
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by day 40 post-doxycycline withdrawal. Regressing tumors that were non-ble of fully reversing the oncogenic effects of MYC. Rather, a
palpable on at least two consecutive occasions were considered to havesmall number of cells persist that are able to survive in the
fully regressed.absence of MYC overexpression and remain one step removed
from frank malignancy. Northern analysis
Notably, even those partially regressing primary tumors that Snap-frozen tissue was homogenized in guanidine thiocyanate supple-
rapidly resume growth following MYC downregulation do so mented with 7 l/ml 2-mercaptoethanol, and RNA isolated by centrifugation
through cesium chloride as previously described (Rajan et al., 1996). Totalonly after first exhibiting substantial regression, in most cases
RNA (3 g per blot) was separated on a 1% LE agarose gel and passivelyto less than one-third of their initial size. This indicates that
transferred to Gene Screen (NEN). Northern hybridization was performedthe majority of cells within even MYC-independent mammary
per manufacturer’s instructions using PerfectHyb Plus Hybridization Buffertumors are, in fact, dependent upon MYC for their survival.
(Sigma) and a 32P-labeled cDNA probe containing a portion of exon 2 of
However, while sustained c-MYC inactivation results in the human c-MYC, or with a cDNA probe from exon 1 of murine c-myc.
death of most cells within primary tumors, the existence within
tumors of even a small number of cells that lack this requirement TUNEL analysis
for MYC results in rapid treatment failure. As such, our findings Mammary adenocarcinomas were harvested and fixed overnight in 4%para-
formaldehyde, transferred to 70% ETOH, and embedded in paraffin. 5 memphasize that clinically important aspects of tumor behavior,
sections on ProbeOn Plus (Fisher) slides were dewaxed in xylene, thensuch as recurrence, resistance, and relapse, are due to small—
sequentially rehydrated in 100%, 95%, and 70% ETOH, followed by phos-yet biologically critical—subsets of cells within tumors.
phate-buffered saline (PBS). TUNEL analysis was performed using the Apop-
Finally, it is worth noting that reconciling the conflicting ob- tag Peroxidase In Situ Apoptosis Detection Kit (Chemicon) according to
servations that have beenmade regarding the oncogene depen- manufacturer’s instructions. Sections were pretreated in Proteinase K (20
dence of MYC-induced neoplasias may, in part, be a matter of g/ml) for 15 min at RT, washed in deionized water twice for 2 min each,
and returned to 1 PBS. Sections were then covered with equilibrationperspective. On one hand, the dramatic regression of primary
buffer for a minimum of 2 min followed by incubation at 37C for 1 hrtumors that occurs following the abrogation of MYC expression
with a 1:10 dilution of TdT enzyme in 1 reaction buffer. Reactions werein multiple tumor types—including many mammary tumors—
terminated, developed using anti-digoxigenin-alkaline phosphatase fab frag-represents an encouraging proof-of-principle that the vast ma-
ments (Roche) and NBT/BCIP ready-to-use tablets (Roche) per manufactur-
jority of tumor cells bearing multiple genetic and epigenetic er’s instructions, and counterstained with nuclear fast red (Vector Labs).
alterations may nevertheless remain dependent upon MYC for Control slides were used consisting of sections from involuting mammary
their maintenance. However, despite this remarkable degree glands day 2 postlactation.
of oncogene dependence, we demonstrate that MYC-induced
Kras2 mutation analysismammary tumors typically progress to more aggressive states
cDNA was generated per manufacturer’s instructions using First-Strandcapable of growth in the absence of MYC pathway activation
cDNA Synthesis Kit (Amersham Biosciences). DNA fragments from Kras2and thereby result in the death of the host. Balancing the encour-
were PCR-amplified, purified, and sequenced as previously described
aging extent to which complex tumors can remain dependent (D’Cruz et al., 2001).
upon a single oncogenicmutationwith the familiar clinical lesson
that cancers treated with single agents typically relapse will be FACS analysis
an important next step in determining the most efficacious use Snap-frozen tumor tissuewas lysed in hypotonic buffer containing propidium
iodide according to the method of Vindelov (Vindelov, 1977). 20,000 eventsof molecularly targeted agents. Ultimately, elucidating the broad
per tumor sample were analyzed on a FACScan flow cytometer. DNA contentrange of molecular alterations that occur during breast cancer
histograms were generated using ModFit software (Verity Software Houseprogression will facilitate targeting of the multiple synergistic
Inc.)
pathways that contribute to neoplastic progression and en-
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